Leadership in health care private equity since 1986

The Latest News

July 09, 2019

NICE Issues Draft Guidance on the Use of gammaCore for Cluster Headache>

The UK's National Institute for Health and Care Excellence (NICE) draft guidance recommends the use of gammaCore for cluster headache in the National Health Service (NHS)

June 27, 2019

Alphatec Announces Organizational and Corporate Updates>

  • New Appointment to Board of Directors
  • Inclusion in Russell 2000® Index
  • Drawdown on Squadron Credit Facility
June 27, 2019

TriSalus Life Sciences Forms World-Class Scientific Advisory Board to Accelerate Advancement of Strategy to Deliver Therapeutics to Solid Tumors>

New Board comprised of preeminent experts across medical, surgical and radiation oncology, s well as immunology

June 24, 2019

ElectroCore Announces gammaCore Listing on the NHS Supply Chain Catalogue>

Provides UK-based primary headache patients not eligible for the Innovation Technology Payment scheme (reserved for treatment-refractory cluster headache patients) an alternative route to access the benefits of nVNS therapy

June 19, 2019

SupplyPro Featured in Technology Headlines Magazine 's May 2019 Issue>

10 Fastest Growing Inventory Management Solution Providers to Watch in 2019

May 30, 2019

Alphatec Announces Commercial Launch of TLIF IdentiTi™ Posterior Curved Porous Titanium Interbody Implant System>

Innovative machine marks the fourth of twelve new product launches planned for 2019, and the third of six IdentiTi implant systems the Company expects to commercially introduce in 2019.

May 20, 2019

UCB announces NAYZILAM® (midazolam) nasal spray now approved by FDA to treat intermittent, stereotypic episodes of frequent seizure activity in people living with epilepsy in the U.S.>

  • NAYZILAM® (midazolam) nasal spray* is a nasally administered benzodiazepine indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.    
  • NAYZILAM allows for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs.
  • Approval of NAYZILAM adds to UCB’s already existing anti-epilepsy drug portfolio, reinforcing the company’s position as a global leader in epilepsy.
April 24, 2019

Exagen's New Biomarker Available to Offer Insight into Thrombosis for Lupus Sufferers>

Lupus Patients with Elevated PC4d Levels Have Significantly Increased Occurrence of Thrombosis

April 15, 2019

Alphatec Announces Sales Leadership Appointment And Successful Closing Of Expanded Credit Facility With Squadron Capital>

Experienced Spine Executive David Sponsel Assumes Sales Leadership Role

March 28, 2019

Alphatec Announces Commercial Launch Of Its First IdentiTi™ Porous Titanium Interbody System>

IdentiTi implants are 60% porous, which enhances intra-operative and post-operative imaging.

 

March 27, 2019

ElectroCore Announces Fourth Quarter and Full Year 2018 Financial Results>

Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018

March 26, 2019

Jeffrey Thomas Elliott, CFA Joins Exagen’s Board of Directors>

Jeff Elliott adds relevant experience to Exagen’s Board of Directors as a former diagnostics analyst at Robert W. Baird & Co. and as the current CFO of Exact Sciences
March 14, 2019

ElectroCore Announces Encouraging Research Supporting Key Areas of Clinical Development for its Non-Invasive Vagus Nerve Stimulator, gammaCore™>

Data presented at the 3rd International Brain Stimulation Conference support the use of nVNS for treatment of mild traumatic brain injury and rheumatoid arthritis

March 08, 2019

ElectroCore Appoints Multiple Industry Veterans to Key Management Positions>

Dr. Tony Fiorino to serve as Chief Medical Officer and Brian Posner as Chief Financial Officer

February 26, 2019

Exagen and the Lupus Foundation of America Partner on New Initiative to Reduce the Time to an Accurate Lupus Diagnosis>

New tools and resources will be shared in English and Spanish through physican offices, websites and social media. 

February 26, 2019

ElectroCore Announces Positive Coverage Policies of gammaCore Issued by Highmark>

gammaCore may be medically necessary for the abortive treatment of episodic migraine and episodic cluster headaches

February 25, 2019

Alphatec Announces FDA Clearance Of Its Automated SafeOp Neuromonitoring System>

Addresses Significant Unmet Needs In Spine Surgery

February 19, 2019

ElectroCore and HealthyWomen Announce Partnership>

Patient Program to Increase Awareness of Non-Drug Migraine Therapies

January 08, 2019

ElectroCore Announces Two New Studies and a Publication>

Findings Support the Practical Utility of Non-invasive Vagus Nerve Stimulation in Adults